Patents by Inventor Gregory F. Oxenkrug

Gregory F. Oxenkrug has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivates thereof
    Patent number: 6849654
    Abstract: Compositions comprising 5-methoxy-carbonylamino-N-acetyltryptamine compounds and derivatives thereof for the treatment of depression are disclosed.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: February 1, 2005
    Assignee: Caritas St. Elizabeth's Medical Center of Boston, Inc.
    Inventors: Gregory F. Oxenkrug, Nikolai S. Zefirov, Sergey O. Bachurin
  • Method of treating neurodegenerative disorders
    Patent number: 6353015
    Abstract: This invention relates to the use of N-acetyl-serotonin (NAS) derivatives for the treatment and prophylaxis of neurological injury and neurodegenerative disorders in a mammal.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: March 5, 2002
    Assignee: St. Elizabeth's Medical Center
    Inventors: Gregory F. Oxenkrug, Sergei O. Bachurin, Andrey Zakharovic Afanasiev, Pura J. Requintina
  • Method for treating hypertension
    Patent number: 6063805
    Abstract: The present invention relates to a method of treatment of hypertension in a mammal, particularly a human being. This method comprises the administration of a therapeutically effective hypertension treatment amount of N-acetylserotonin (NAS) to the mammal.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: May 16, 2000
    Assignee: St. Elizabeth's Medical Center of Boston
    Inventors: Gregory F. Oxenkrug, Pura J. Requintina
  • Method for treating depression, obsessive compulsive disorder, and anxiety with N--acetyl serotonin
    Patent number: 6011054
    Abstract: The present invention relates to a method of treatment of depression in a human being identified as having depression. This method comprises the administration of a therapeutically effective depression treatment amount of N-acetyl-serotonin (NAS), also referred to as N-acetyl-5-hydroxytryptamine, to a human being identified as having depression. The NAS may be administered alone or in combination with other agents, e.g., Ca.sup.++ antagonists.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: January 4, 2000
    Assignee: St. Elizabeth's Medical Center of Boston
    Inventors: Gregory F. Oxenkrug, Pura J. Requintina